The Mobile Word Capital Foundation (MWCapital) and Barcelona Health Hub (BHH) have signed a collaboration agreement to support and accompany startups in the health sector created by The Collider and to accelerate their commercialization.
The signing ceremony took place in the Operations Pavilion of the Recinte Modernista de Sant Pau and was led by Oscar Sala, director of The Collider program at MWCapital, and Eva Rosell, general manager of BHH.
The Collider, MWCapital‘s innovation area, aims to transform scientific knowledge into market solutions that respond to the challenges of industry and society. Its training and start-up programs offer support to projects that have already passed the laboratory validation phase but are not yet mature enough to attract market interest, and fosters collaboration between corporations, scientists and entrepreneurs.
This collaboration will facilitate the clinical validation and acceleration process of the projects incubated by The Collider, and their connection with the Barcelona Health Hub ecosystem. Likewise, the BHH team is expected to participate in the technology, industry and investment committees convened by The Collider‘s start-up program.
The general director of Barcelona Health Hub, Eva Rosell, said that “with the growth that is taking place in the digital health sector, the agreement we are signing will help to further accelerate innovation and the design of new technological solutions and their transfer to daily clinical practice. In this way, we will contribute to improving people’s lives and making our healthcare system more sustainable”.
For his part, the director of The Collider program at MWCapital, Oscar Sala, highlighted that this agreement “will help the healthcare startups created at The Collider to improve their activity by forming part of a unique healthcare ecosystem that involves all the actors in the healthcare model. It also reinforces the will of the Mobile World Capital Barcelona Foundation to promote collaboration with the state ecosystem, promoting a greater number of research-company collaborations”.